News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Nektar Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Policy
Nektar Therapeutics Cancer Drug Improves Survival But Misses Primary Endpoint, As Watchers Worry
March 17, 2015
·
4 min read
Job Trends
Booming Nektar Therapeutics (CA) Grabs More Mission Bay Space; May Hire Another 150 Staffers
January 20, 2015
·
1 min read
Biotech Bay
Opioids Without Addiction, Nektar Therapeutics (CA) Reveals
September 4, 2013
·
1 min read
BioCapital
The Day In Review: Big M&A Activity In Biotech
September 21, 2006
·
1 min read
Biotech Beach
The Day In Review: Enzon Pharmaceuticals, Inc. Buys And Sells Drug Progams
July 27, 2006
·
1 min read
Biotech Beach
The Day In Review: Shire Pharmaceuticals Wins Elaprase Approval
July 24, 2006
·
1 min read
Biotech Beach
The Day In Review: Gilead Sciences (Foster City, CA) Pays $365 Million For Corus Pharma, Inc.
July 20, 2006
·
1 min read
Biotech Beach
The Day In Review: Diabetes News Rules
June 13, 2006
·
1 min read
Biotech Beach
The Day In Review: Vertex Pharmaceuticals Incorporated Reveals Positive Hep C Data
May 22, 2006
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Biotech Bay
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan
April 22, 2022
·
1 min read
Biotech Bay
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
April 14, 2022
·
46 min read
Business
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
March 14, 2022
·
45 min read
Drug Development
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial
March 14, 2022
·
1 min read
Business
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
February 28, 2022
·
15 min read
Business
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets
February 17, 2022
·
1 min read
Biotech Bay
Nektar Therapeutics’ President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
January 5, 2022
·
1 min read
Drug Development
Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis
December 15, 2021
·
8 min read
Drug Development
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
December 13, 2021
·
8 min read
Biotech Bay
Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting
November 30, 2021
·
7 min read
